You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: June 23, 2024

~ Buy the BYLVAY (odevixibat) Drug Profile, 2024 PDF Report in the Report Store ~

BYLVAY Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Bylvay, and what generic alternatives are available?

Bylvay is a drug marketed by Ipsen and is included in one NDA. There are eleven patents protecting this drug.

This drug has one hundred and eleven patent family members in forty countries.

The generic ingredient in BYLVAY is odevixibat. Two suppliers are listed for this compound. Additional details are available on the odevixibat profile page.

DrugPatentWatch® Generic Entry Outlook for Bylvay

Bylvay will be eligible for patent challenges on July 20, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 20, 2039. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

Summary for BYLVAY
International Patents:111
US Patents:11
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 2
Raw Ingredient (Bulk) Api Vendors: 15
Drug Prices: Drug price information for BYLVAY
What excipients (inactive ingredients) are in BYLVAY?BYLVAY excipients list
DailyMed Link:BYLVAY at DailyMed
Drug patent expirations by year for BYLVAY
Drug Prices for BYLVAY

See drug prices for BYLVAY

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for BYLVAY
Generic Entry Date for BYLVAY*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE, PELLETS;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BYLVAY

US Patents and Regulatory Information for BYLVAY

BYLVAY is protected by thirty-two US patents and four FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of BYLVAY is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting BYLVAY

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

Crystal modifications of odevixibat
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver diseases
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

Crystal modifications of odevixibat
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

Crystal modifications of odevixibat
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

Crystal modifications of odevixibat
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

Crystal modifications of odevixibat
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up


Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

IBAT inhibitors for the treatment of liver disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING PRURITUS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

IBAT inhibitors for the treatment of liver disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF REDUCING SERUM BILE ACIDS IN PATIENTS 3 MONTHS OR OLDER SUFFERING FROM PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)

IBAT inhibitors for the treatment of liver disease
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: METHOD OF TREATING CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OR OLDER SUFFERING FROM ALAGILLE SYNDROME (ALGS)

FDA Regulatory Exclusivity protecting BYLVAY

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS 12 MONTHS OF AGE AND OLDER WITH ALAGILLE SYNDROME (ALGS)
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PRURITUS IN PATIENTS 3 MONTHS OF AGE AND OLDER WITH PROGRESSIVE FAMILIAL INTRAHEPATIC CHOLESTASIS (PFIC)
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BYLVAY

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipsen BYLVAY odevixibat CAPSULE;ORAL 215498-004 Jul 20, 2021 ⤷  Sign Up ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-001 Jul 20, 2021 ⤷  Sign Up ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE;ORAL 215498-002 Jul 20, 2021 ⤷  Sign Up ⤷  Sign Up
Ipsen BYLVAY odevixibat CAPSULE, PELLETS;ORAL 215498-003 Jul 20, 2021 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

EU/EMA Drug Approvals for BYLVAY

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Albireo Bylvay odevixibat EMEA/H/C/004691
Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1).
Authorised no no yes 2021-07-16
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for BYLVAY

When does loss-of-exclusivity occur for BYLVAY?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Patent: 19290337
Patent: Crystal modifications of odevixibat
Estimated Expiration: ⤷  Sign Up

Patent: 19290338
Patent: Pharmaceutical formulation of odevixibat
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2020024461
Patent: formulação farmacêutica de odevixibat, processo para a preparação da formulação farmacêutica, e, formulação.
Estimated Expiration: ⤷  Sign Up

Patent: 2020024479
Patent: hidrato cristalino, modificações cristalinas de odevixibat, solvato misto de odevixibat, uso de modificação cristalina de odevixibat, processo para a preparação de modificação cristalina de odevixibat, e, composição farmacêutica
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 00687
Patent: FORMULATION PHARMACEUTIQUE A BASE D'ODEVIXIBAT (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Patent: 00691
Patent: MODIFICATIONS CRISTALLINES D'ODEVIXIBAT (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 20003295
Patent: Modificaciones de cristales de odexibat
Estimated Expiration: ⤷  Sign Up

Patent: 20003296
Patent: Formulación farmacéutica de odevixibat
Estimated Expiration: ⤷  Sign Up

China

Patent: 2262130
Patent: 奥德昔巴特的结晶修饰物 (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Patent: 2312893
Patent: 奥德昔巴特的药物制剂 (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 20015772
Patent: Formulación farmacéutica de odevixibat
Estimated Expiration: ⤷  Sign Up

Patent: 20015781
Patent: Modificaciones de cristales de odexibat
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 210026
Patent: MODIFICACIONES DE CRISTALES DE ODEVIXIBAT (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Patent: 210027
Patent: FORMULACIÓN FARMACÉUTICA DE ODEVIXIBAT (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 21000999
Patent: MODIFICACIONES DE CRISTALES DE ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Patent: 21001547
Patent: FORMULACIÓN FARMACÉUTICA DE ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 10084
Patent: FORMULATION PHARMACEUTIQUE À BASE D'ODÉVIXIBAT (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Patent: 10581
Patent: MODIFICATIONS CRISTALLINES D'ODÉVIXIBAT (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 9464
Patent: פורמולציה רוקחית של אודוויקסיבאט (Pharmaceutical formulation of odevixibat)
Estimated Expiration: ⤷  Sign Up

Patent: 9468
Patent: שינויי גביש של אודוויקסיבאט (Crystal modifications of odevixibat)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 48490
Estimated Expiration: ⤷  Sign Up

Patent: 21528415
Patent: オデビキシバットの医薬製剤
Estimated Expiration: ⤷  Sign Up

Patent: 21528416
Patent: オデビキシバットの結晶変態
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 0200297
Patent: تعديلات بلورية للأوديفيكسيبات (CRYSTAL MODIFICATIONS OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Patent: 0200299
Patent: صيغة صيدلانية لأوديفيكسيبات (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT)
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 20013774
Patent: MODIFICACIONES DE CRISTALES DE ODEVIXIBAT. (CRYSTAL MODIFICATIONS OF ODEVIXIBAT.)
Estimated Expiration: ⤷  Sign Up

Patent: 20013839
Patent: FORMULACION FARMACEUTICA DE ODEVIXIBAT. (PHARMACEUTICAL FORMULATION OF ODEVIXIBAT.)
Estimated Expiration: ⤷  Sign Up

Nicaragua

Patent: 2000103
Patent: MODIFICACIONES DE CRISTALES DE ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Patent: 2000104
Patent: FORMULACIÓN FARMACÉUTICA DE ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 210136
Patent: FORMULACION FARMACEUTICA DE ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Patent: 210182
Patent: MODIFICACIONES DE CRISTALES DE ODEXIBAT
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 020552165
Patent: PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Patent: 020552168
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 202012151X
Patent: CRYSTAL MODIFICATIONS OF ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Patent: 202012170P
Patent: PHARMACEUTICAL FORMULATION OF ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 210024032
Patent: 오데빅시바트의 결정 변형물
Estimated Expiration: ⤷  Sign Up

Patent: 210024033
Patent: 오데빅시바트의 약학 제제
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 23954
Estimated Expiration: ⤷  Sign Up

Patent: 2012381
Patent: Crystal modifications of ODEVIXIBAT
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering BYLVAY around the world.

Country Patent Number Title Estimated Expiration
European Patent Office 3023102 INHIBITEURS IBAT POUR LE TRAITEMENT DE MALADIES DU FOIE (IBAT INHIBITORS FOR THE TREATMENT OF LIVER DISEASES) ⤷  Sign Up
Malaysia 163275 ⤷  Sign Up
Australia 2019290338 Pharmaceutical formulation of odevixibat ⤷  Sign Up
Chile 2020003296 Formulación farmacéutica de odevixibat ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for BYLVAY

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
3400944 48/2021 Austria ⤷  Sign Up PRODUCT NAME: ODEVIXIBAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/21/1566 (MITTEILUNG) 20210719
3400944 2190043-6 Sweden ⤷  Sign Up PRODUCT NAME: ODEVIXIBAT; REG. NO/DATE: EU/1/21/1556 20210719
3400944 SPC/GB21/078 United Kingdom ⤷  Sign Up PRODUCT NAME: ODEVIXIBAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING ODEVIXIBAT SESQUIHYDRATE; REGISTERED: UK EU/1/21/1566(NI) 20210719; UK PLGB 36216/0001 20210719; UK PLGB 36216/0002 20210719
3400944 CR 2022 00001 Denmark ⤷  Sign Up PRODUCT NAME: ODEVIXIBAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/21/1566 20210719
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.